TSTickerStarGet alerts

Artelo Biosciences Reports Q3 2026 Financial Results

Artelo Biosciences reported a Q3 2026 net loss of $1.8 million or $3.19 per basic and diluted common share, compared to a net loss of $3.1 million in Q3 2025. R&D expenses decreased to $0.8 million from $1.3 million year-over-year, while G&A expenses declined to $1.0 million from $1.8 million. The company ended the quarter with $4.4 million in cash.

Share this story

Key takeaways

  • Q3 2026 net loss was $1.8 million compared to $3.1 million in Q3 2025, a reduction in loss of $1.3 million.

  • R&D expenses decreased to $0.8 million in Q3 2026 from $1.3 million in Q3 2025.

  • G&A expenses declined to $1.0 million in Q3 2026 from $1.8 million in Q3 2025.

  • Cash and investments totaled $4.4 million as of September 30, 2026.

  • ART27.13 demonstrated approximately 20% weight loss as monotherapy and 40% weight loss when combined with semaglutide in diet-induced obesity animal model.

  • Phase 2 DREAM trial initiated for ART27.13 in glaucoma with enrollment underway.

  • Phase 1 MAD study for ART26.12 planned to initiate in Q4 2026.

Key metrics

Net LossQ3 2026
$1.8 million$1.3 million improvement vs Q3 2025
EPS (Basic and Diluted)Q3 2026
$3.19
Research and Development ExpensesQ3 2026
$0.8 million$0.5 million decrease vs Q3 2025
General and Administrative ExpensesQ3 2026
$1.0 million$0.8 million decrease vs Q3 2025
Cash and InvestmentsQ3 2026
$4.4 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open Investor relations

Follow ARTL in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert